

He further added, "In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of 'start-to-finish' technologies that will help them improve product yields and reduce time-to-market."

GE's acquisition of the businesses is anticipated to close in 2014 after receiving necessary regulatory approvals.

The three acquired businesses combined annual revenues were approximately \$250 million in 2013 said the press release on Monday.